SOPHiA GENETICS (NASDAQ: SOPH) insider exercises options, sells 20,000 shares
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief Scientific Officer Xu Zhenyu reported option exercises and share sales in early August 2026. He exercised options for 10,000 Ordinary Shares at $3.2800 per share and sold 20,000 Ordinary Shares at prices between $7.00 and $7.56 under a Rule 10b5-1(c) trading plan, while retaining 975,041 derivative share options.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
7 txns
Insider
Xu Zhenyu
Role
Chief Scientific Officer
Sold
20,000 shs ($145K)
Approx. gross sale proceeds
$145K
Approx. exercise cost
$33K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (Right to Buy) F4, F6 | 7,000 | $3.28 | $23K |
| Exercise | Ordinary Shares F1 | 7,000 | $3.28 | $23K |
| Sale | Ordinary Shares F1, F2 | 7,000 | $7.0217 | $49K |
| Sale | Ordinary Shares F1, F3 | 10,000 | $7.4759 | $75K |
| Exercise | Share Option (Right to Buy) F1, F4, F5 | 3,000 | $3.28 | $10K |
| Exercise | Ordinary Shares F1 | 3,000 | $3.28 | $10K |
| Sale | Ordinary Shares F1 | 3,000 | $7.0043 | $21K |
Holdings After Transaction:
Share Option (Right to Buy) — 0 shares (Direct);
Ordinary Shares — 590,887 shares (Direct)
Footnotes (6)
- F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.00 to $7.08, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.40 to $7.56, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The share options are fully vested and exercisable.
- F5. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 982,041 derivative share options across all remaining grant tranches with varying exercise prices.
- F6. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 975,041 derivative share options across all remaining grant tranches with varying exercise prices.
Key Figures
Total Ordinary Shares sold: 20000 shares
Shares underlying options exercised: 10000 shares
Option exercise price: $3.2800 per share
+4 more
7 metrics
Total Ordinary Shares sold
20000 shares
Aggregate Ordinary Shares sold on 2026-08-05 and 2026-08-07
Shares underlying options exercised
10000 shares
Total Ordinary Shares acquired through option exercises in August 2026
Option exercise price
$3.2800 per share
Exercise price for Share Option (Right to Buy) derivatives
Sale price for 3000 shares
$7.0043 per share
Ordinary Shares sale on 2026-08-05
Sale price for 7000 shares
$7.0217 per share
Ordinary Shares sale on 2026-08-07 with weighted average range $7.00–$7.08
Sale price for 10000 shares
$7.4759 per share
Ordinary Shares sale on 2026-08-07 with weighted average range $7.40–$7.56
Derivative options remaining after final transaction
975,041 options
Derivative share options held after 2026-08-07 transaction
Key Terms
Rule 10b5-1(c), weighted average price, derivative share options, Share Option (Right to Buy)
4 terms
Rule 10b5-1(c) regulatory
"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Xu Zhenyu report for SOPH in this Form 4?
Xu Zhenyu, Chief Scientific Officer of SOPHiA GENETICS, reported exercising options for 10,000 Ordinary Shares at $3.2800 per share and selling 20,000 Ordinary Shares on August 5 and 7, 2026, under a pre-arranged Rule 10b5-1(c) trading plan.
What SOPH stock options did Xu Zhenyu exercise in the reported period?
On August 5 and 7, 2026, he exercised fully vested share options covering 10,000 Ordinary Shares in total at an exercise price of $3.2800 per share. These options, titled “Share Option (Right to Buy),” are reported with an expiration date of 2027-09-05.
How many SOPH derivative options does Xu Zhenyu still hold after these trades?
After the August 5 transaction, he held 982,041 derivative share options across remaining grant tranches. Following the August 7 exercise, he held 975,041 derivative share options, according to the footnotes, all with varying exercise prices that are not detailed individually.
Were Xu Zhenyu’s SOPH transactions made under a Rule 10b5-1 trading plan?
Yes. A company-level checkbox affirms use of a Rule 10b5-1 plan, and footnote F1 states each reported transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c), indicating the trades were pre-arranged rather than discretionary market-timing decisions.